|
1
|
Ostrom QT, Bauchet L, Davis FG, Deltour I,
Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh
KM, et al: The epidemiology of glioma in adults: A ‘state of the
science’ review. Neuro Oncol. 16:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bailey P and Cushing H: Microchemical
color reactions as an aid to the identification and classification
of brain tumors. Proc Natl Acad Sci USA. 11:82–84. 1925. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Masui K, Cloughesy TF and Mischel PS:
Review: Molecular pathology in adult high-grade gliomas: From
molecular diagnostics to target therapies. Neuropathol Appl
Neurobiol. 38:271–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van den Bent MJ: Interobserver variation
of the histopathological diagnosis in clinical trials on glioma: A
clinician's perspective. Acta Neuropathol. 120:297–304. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen R, Smith-Cohn M, Cohen AL and Colman
H: Glioma subclassifications and their clinical significance.
Neurotherapeutics. 14:284–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perry A and Wesseling P: Histologic
classification of gliomas. Handb Clin Neurol. 134:71–95. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cancer Genome Atlas Research Network, .
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA,
Rheinbay E, Miller CR, Vitucci M, et al: Comprehensive, integrative
genomic analysis of diffuse lower-grade gliomas. N Engl J Med.
372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleihues P, Burger PC and Scheithauer BW:
The new WHO classification of brain tumours. Brain Pathol.
3:255–268. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patel AP, Tirosh I, Trombetta JJ, Shalek
AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT,
Martuza RL, et al: Single-cell RNA-seq highlights intratumoral
heterogeneity in primary glioblastoma. Science. 344:1396–1401.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neftel C, Laffy J, Filbin MG, Hara T,
Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM,
et al: An integrative model of cellular states, plasticity, and
genetics for glioblastoma. Cell. 178:835–849.e21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Couturier CP, Ayyadhury S, Le PU, Nadaf J,
Monlong J, Riva G, Allache R, Baig S, Yan X, Bourgey M, et al:
Single-cell RNA-seq reveals that glioblastoma recapitulates a
normal neurodevelopmental hierarchy. Nat Commun. 11:34062020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martínez AH, Madurga R, García-Romero N
and Ayuso-Sacido Á: Unraveling glioblastoma heterogeneity by means
of single-cell RNA sequencing. Cancer Lett. 527:66–79. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martinez R, Schackert HK, Plaschke J,
Baretton G, Appelt H and Schackert G: Molecular mechanisms
associated with chromosomal and microsatellite instability in
sporadic glioblastoma multiforme. Oncology. 66:395–403. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tepeoglu M, Borcek P, Ozen O and Altinors
N: Microsatellite instability in glioblastoma: Is it really
relevant in tumor prognosis? Turk Neurosurg. 29:778–784.
2019.PubMed/NCBI
|
|
17
|
Agnihotri S and Zadeh G: Metabolic
reprogramming in glioblastoma: The influence of cancer metabolism
on epigenetics and unanswered questions. Neuro Oncol. 18:160–172.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deshmukh R, Allega MF and Tardito S: A map
of the altered glioma metabolism. Trends Mol Med. 27:1045–1059.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Virtuoso A, Giovannoni R, De Luca C,
Gargano F, Cerasuolo M, Maggio N, Lavitrano M and Papa M: The
glioblastoma microenvironment: Morphology, metabolism, and
molecular signature of glial dynamics to discover metabolic
rewiring sequence. Int J Mol Sci. 22:33012021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee H, Kim D and Youn B: Targeting
oncogenic rewiring of lipid metabolism for glioblastoma treatment.
Int J Mol Sci. 23:138182022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andersen RS, Anand A, Harwood DSL and
Kristensen BW: Tumor-associated microglia and macrophages in the
glioblastoma microenvironment and their implications for therapy.
Cancers (Basel). 13:42552021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JH and Lee HK: Current understanding
of hypoxia in glioblastoma multiforme and its response to
immunotherapy. Cancers (Basel). 14:11762022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lamborn KR, Chang SM and Prados MD:
Prognostic factors for survival of patients with glioblastoma:
Recursive partitioning analysis. Neuro Oncol. 6:227–235. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stoyanov GS, Dzhenkov D, Ghenev P, Iliev
B, Enchev Y and Tonchev AB: Cell biology of glioblastoma
multiforme: From basic science to diagnosis and treatment. Med
Oncol. 35:272018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: The somatic genomic landscape of glioblastoma.
Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Godek KM, Venere M, Wu Q, Mills KD, Hickey
WF, Rich JN and Compton DA: Chromosomal instability affects the
tumorigenicity of glioblastoma tumor-initiating cells. Cancer
Discov. 6:532–545. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buruiană A, Florian ȘI, Florian AI, Timiș
TL, Mihu CM, Miclăuș M, Oșan S, Hrapșa I, Cataniciu RC, Farcaș M,
et al: The roles of miRNA in glioblastoma tumor cell communication:
Diplomatic and aggressive negotiations. Int J Mol Sci. 21:19502020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mafi A, Rahmati A, Aghdam ZB, Salami R,
Salami M, Vakili O and Aghadavod E: Recent insights into the
microRNA-dependent modulation of gliomas from pathogenesis to
diagnosis and treatment. Cell Mol Biol Lett. 27:652022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tluli O, Al-Maadhadi M, Al-Khulaifi AA,
Akomolafe AF, Al-Kuwari SY, Al-Khayarin R, Maccalli C and Pedersen
S: Exploring the role of microRNAs in glioma progression,
prognosis, and therapeutic strategies. Cancers (Basel).
15:42132023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stackhouse CT, Gillespie GY and Willey CD:
Exploring the roles of lncRNAs in GBM pathophysiology and their
therapeutic potential. Cells. 9:23692020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bagheri-Mohammadi S, Karamivandishi A,
Mahdavi SA and Siahposht-Khachaki A: New sights on long non-coding
RNAs in glioblastoma: A review of molecular mechanism. Heliyon.
10:e397442024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hashemi M, Roshanzamir SM, Orouei S,
Daneii P, Raesi R, Zokaee H, Bikarannejad P, Salmani K, Khorrami R,
Paskeh MDA, et al: Shedding light on function of long non-coding
RNAs (lncRNAs) in glioblastoma. Noncoding RNA Res. 9:508–522. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brat DJ, Aldape K, Colman H, Holland EC,
Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A,
Reifenberger G, Stupp R, et al: cIMPACT-NOW update 3: Recommended
diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype,
with molecular features of glioblastoma, WHO grade IV’. Acta
Neuropathol. 136:805–810. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tesileanu CMS, Dirven L, Wijnenga MMJ,
Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM,
van Duinen SG, Smits M, et al: Survival of diffuse astrocytic
glioma, IDH1/2 wildtype, with molecular features of glioblastoma,
WHO grade IV: A confirmation of the cIMPACT-NOW criteria. Neuro
Oncol. 4:515–523. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang B, Gu X, Han X, Gao Q, Liu J, Guo T
and Gao D: Crosstalk between DNA methylation and histone
acetylation triggers GDNF high transcription in glioblastoma cells.
Clin Epigenetics. 12:472020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Azab MA: The potential role of histone
modifications in glioblastoma therapy: Review article. J Mol
Pathol. 4:Article 4. 2023. View Article : Google Scholar
|
|
39
|
McCornack C, Woodiwiss T, Hardi A, Yano H
and Kim AH: The function of histone methylation and acetylation
regulators in GBM pathophysiology. Front Oncol. 13:11441842023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rama AR, Alvarez PJ, Madeddu R and Aranega
A: ABC transporters as differentiation markers in glioblastoma
cells. Mol Biol Rep. 41:4847–4851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ahmed M, Verreault M, Declèves X and
Idbaih A: Role of multidrug resistance in glioblastoma
chemoresistance: Focus on ABC transporters. Cancer sensitizing
agents for chemotherapy, glioblastoma resistance to chemotherapy:
Molecular mechanisms and innovative reversal strategies.
Paulmurugan R and Massoud TF: Academic Press; 15. pp. 243–261.
2021
|
|
42
|
Canzoneri R, Lacunza E and Abba MC:
Genomics and bioinformatics as pillars of precision medicine in
oncology. Medicina (B Aires). 79:587–592. 2019.PubMed/NCBI
|
|
43
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu P, Heins ZJ, Muller JT, Katsnelson L,
de Bruijn I, Abeshouse AA, Schultz N, Fenyö D and Gao J:
Integration and analysis of CPTAC proteomics data in the context of
cancer genomics in the cBioPortal. Mol Cell Proteomics.
18:1893–1898. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brlek P, Kafka A, Bukovac A and
Pećina-Šlaus N: Integrative cBioPortal analysis revealed molecular
mechanisms that regulate EGFR-PI3K-AKT-mTOR pathway in diffuse
gliomas of the brain. Cancers (Basel). 13:32472021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ahsan H, Asghar M and Malik SI: Potential
diagnostic and drug target markers in glioblastoma. Sci Rep.
14:72922024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dhar C: Utilizing publicly available
cancer clinicogenomic data on cBioPortal to compare epidermal
growth factor receptor mutant and wildtype non-small cell lung
cancer. Cureus. 13:e146832021.PubMed/NCBI
|
|
48
|
Reimer N, Unberath P, Busch H, Börries M,
Metzger P, Ustjanzew A, Renner C, Prokosch HU and Christoph J:
Challenges and experiences extending the cBioPortal for cancer
genomics to a molecular tumor board platform. Stud Health Technol
Inform. 18:139–143. 2021.PubMed/NCBI
|
|
49
|
Kohl M, Wiese S and Warscheid B:
Cytoscape: Software for visualization and analysis of biological
networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Donaldson IM: Protein interaction data
resources. Handbook of cell signaling. 2nd Edition. Academic Press;
San Diego, CA: pp. 1375–1385. 2010, View Article : Google Scholar
|
|
52
|
Jean-Quartier C, Jeanquartier F and
Holzinger A: Open data for differential network analysis in glioma.
Int J Mol Sci. 21:5472020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ma T and Zhang A: Integrate multi-omics
data with biological interaction networks using multi-view
factorization AutoEncoder (MAE). BMC Genomics. 20 (Suppl
11):S9442019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Picard M, Scott-Boyer MP, Bodein A, Périn
O and Droit A: Integration strategies of multi-omics data for
machine learning analysis. Comput Struct Biotechnol J.
19:3735–3746. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sanches PHG, de Melo NC, Porcari AM and de
Carvalho LM: Integrating molecular perspectives: Strategies for
comprehensive multi-omics integrative data analysis and machine
learning applications in transcriptomics, proteomics, and
metabolomics. Biology (Basel). 13:8482024.PubMed/NCBI
|
|
56
|
Zhou Y, Yang L, Zhang X, Chen R, Chen X,
Tang W and Zhang M: Identification of potential biomarkers in
glioblastoma through bioinformatic analysis and evaluating their
prognostic value. Biomed Res Int. 2019:65815762019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Erasimus H, Gobin M, Niclou S and Van Dyck
E: DNA repair mechanisms and their clinical impact in glioblastoma.
Mutat Res Rev Mutat Res. 769:19–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu Y, Song Y, Wang R and Wang T: Molecular
mechanisms of tumor resistance to radiotherapy. Mol Cancer.
22:962023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stockhausen MT, Kristoffersen K and
Poulsen HS: The functional role of notch signaling in human
gliomas. Neuro Oncol. 12:199–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bazzoni R and Bentivegna A: Role of notch
signaling pathway in glioblastoma pathogenesis. Cancers (Basel).
11:2922019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stenson PD, Mort M, Ball EV, Shaw K,
Phillips A and Cooper DN: The human gene mutation database:
Building a comprehensive mutation repository for clinical and
molecular genetics, diagnostic testing and personalized genomic
medicine. Hum Genet. 133:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
1,000 Genomes Project Consortium, .
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker
RE, Kang HM, Marth GT and McVean GA: An integrated map of genetic
variation from 1,092 human genomes. Nature. 491:56–65. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Garcia FAO, de Andrade ES and Palmero EI:
Insights on variant analysis in silico tools for pathogenicity
prediction. Front Genet. 13:10103272022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Steinhaus R, Proft S, Schuelke M, Cooper
DN, Schwarz JM and Seelow D: MutationTaster2021. Nucleic Acids Res.
49:W446–W451. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Crespo I, Vital AL, Gonzalez-Tablas M,
Patino MDC, Otero A, Lopes MC, de Oliveira C, Domingues P, Orfao A
and Tabernero MD: Molecular and genomic alterations in glioblastoma
multiforme. Am J Pathol. 185:1820–1833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Binder ZA, Thorne AH, Bakas S, Wileyto EP,
Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, et al:
Epidermal growth factor receptor extracellular domain mutations in
glioblastoma present opportunities for clinical imaging and
therapeutic development. Cancer Cell. 34:163–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lu KV, Zhu S, Cvrljevic A, Huang TT,
Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I,
et al: Fyn and SRC are effectors of oncogenic epidermal growth
factor receptor signaling in glioblastoma patients. Cancer Res.
69:6889–6898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nagane M, Coufal F, Lin H, Bögler O,
Cavenee WK and Huang HJ: A common mutant epidermal growth factor
receptor confers enhanced tumorigenicity on human glioblastoma
cells by increasing proliferation and reducing apoptosis. Cancer
Res. 56:5079–5086. 1996.PubMed/NCBI
|
|
70
|
Jain A, Penuel E, Mink S, Schmidt J, Hodge
A, Favero K, Tindell C and Agus DB: HER kinase axis receptor dimer
partner switching occurs in response to EGFR tyrosine kinase
inhibition despite failure to block cellular proliferation. Cancer
Res. 70:1989–1999. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sathornsumetee S and Rich JN: Designer
therapies for glioblastoma multiforme. Ann N Y Acad Sci.
1142:108–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Huang TT, Sarkaria SM, Cloughesy TF and
Mischel PS: Targeted therapy for malignant glioma patients: Lessons
learned and the road ahead. Neurotherapeutics. 6:500–512. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
El Atat O, Naser R, Abdelkhalek M, Habib
RA and El Sibai M: Molecular targeted therapy: A new avenue in
glioblastoma treatment. Oncol Lett. 25:462022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ezzati S, Salib S, Balasubramaniam M and
Aboud O: Epidermal growth factor receptor inhibitors in
glioblastoma: Current status and future possibilities. Int J Mol
Sci. 25:23162024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Vivanco I, Robins HI, Rohle D, Campos C,
Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N,
et al: Differential sensitivity of glioma-versus lung
cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer
Discov. 2:458–471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hegi ME, Diserens AC, Bady P, Kamoshima Y,
Kouwenhoven MCM, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch
A, et al: Pathway analysis of glioblastoma tissue after
preoperative treatment with the EGFR tyrosine kinase inhibitor
gefitinib-A phase II trial. Mol Cancer Ther. 10:1102–1112. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Neyns B, Sadones J, Joosens E, Bouttens F,
Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, Veld PI,
et al: Stratified phase II trial of cetuximab in patients with
recurrent high-grade glioma. Ann Oncol. 20:1596–1603. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Westphal M, Heese O, Steinbach JP, Schnell
O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C,
et al: A randomized, open-label phase III trial with nimotuzumab,
an anti-epidermal growth factor receptor monoclonal antibody in the
treatment of newly diagnosed adult glioblastoma. Eur J Cancer.
51:522–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nitta Y, Shimizu S, Shishido-Hara Y,
Suzuki K, Shiokawa Y and Nagane M: Nimotuzumab enhances
temozolomide-induced growth suppression of glioma cells expressing
mutant EGFR in vivo. Cancer Med. 5:486–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hasselbalch B, Lassen U, Hansen S,
Holmberg M, Sorensen M, Kosteljanetz M, Broholm H, Stockhausen MT
and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients
with primary glioblastoma and progression after radiation therapy
and temozolomide: A phase II trial. Neuro Oncol. 12:508–516.
2010.PubMed/NCBI
|
|
81
|
McCrea HJ, Ivanidze J, O'Connor A, Hersh
EH, Boockvar JA, Gobin YP, Knopman J and Greenfield JP:
Intraarterial delivery of bevacizumab and cetuximab utilizing
blood-brain barrier disruption in children with high-grade glioma
and diffuse intrinsic pontine glioma: Results of a phase I trial. J
Neurosurg Pediatr. 28:371–379. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pérez-Soler R, Delord JP, Halpern A, Kelly
K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières
D, et al: HER1/EGFR inhibitor-associated rash: Future directions
for management and investigation outcomes from the HER1/EGFR
inhibitor rash management forum. Oncologist. 10:345–356. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Thomas M: Cetuximab: Adverse event profile
and recommendations for toxicity management. Clin J Oncol Nurs.
9:332–338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Keir ST, Chandramohan V, Hemphill CD,
Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins
A, Friedman HS and Bigner DD: Sym004-induced EGFR elimination is
associated with profound anti-tumor activity in EGFRvIII
patient-derived glioblastoma models. J Neurooncol. 138:489–498.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Shikalov A, Koman I and Kogan NM: Targeted
glioma therapy-clinical trials and future directions.
Pharmaceutics. 16:1002024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lim Y, Yoo J, Kim MS, Hur M, Lee EH, Hur
HS, Lee JC, Lee SN, Park TW, Lee K, et al: GC1118, an anti-EGFR
antibody with a distinct binding epitope and superior inhibitory
activity against high-affinity EGFR ligands. Mol Cancer Ther.
15:251–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Choi SW, Jung HA, Cho H, Kim TM, Park CK,
Nam DH and Lee SH: A multicenter, phase II trial of GC1118, a novel
anti-EGFR antibody, for recurrent glioblastoma patients with EGFR
amplification. Cancer Med. 12:15788–15796. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lassman AB, van den Bent MJ, Gan HK,
Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors
LB, Papadopoulos KP, et al: Safety and efficacy of depatuxizumab
mafodotin + temozolomide in patients with EGFR-amplified, recurrent
glioblastoma: Results from an international Phase I multicenter
trial. Neuro Oncol. 21:106–114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Desjardins A, Chandramohan V, Landi DB,
Johnson MO, Khasraw M, Peters KB, Low J, Herndon JE, Threatt S,
Bullock CA, et al: A phase I trial of D2C7-IT in combination with
an Fc-engineered anti-CD40 monoclonal antibody (2141-V11)
administered intratumorally via convection-enhanced delivery for
adult patients with recurrent malignant glioma (MG). J Clin Oncol.
40 (Suppl):e140152022. View Article : Google Scholar
|
|
90
|
Kowalewski A, Durślewicz J, Zdrenka M,
Grzanka D and Szylberg Ł: Clinical relevance of BRAF V600E mutation
status in brain tumors with a focus on a novel management
algorithm. Target Oncol. 15:531–540. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Etcheverry A, Aubry M, de Tayrac M,
Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L,
Menei P, et al: DNA methylation in glioblastoma: Impact on gene
expression and clinical outcome. BMC Genomics. 11:7012010.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Klughammer J, Kiesel B, Roetzer T,
Fortelny N, Kuchler A, Nenning KH, Furtner J, Sheffield NC,
Datlinger P, Peter N, et al: The DNA methylation landscape of
glioblastoma disease progression shows extensive heterogeneity in
time and space. Nat Med. 24:1611–1624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Mao YK, Liu ZB and Cai L: Identification
of glioblastoma-specific prognostic biomarkers via an integrative
analysis of DNA methylation and gene expression. Oncol Lett.
20:1619–1628. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Sun X, Yuan W, Hao F and Zhuang W:
Promoter methylation of RASSF1A indicates prognosis for patients
with stage II and III colorectal cancer treated with
oxaliplatin-based chemotherapy. Med Sci Monit. 23:5389–5395. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Szklener K, Mazurek M, Wieteska M,
Wacławska M, Bilski M and Mańdziuk S: New directions in the therapy
of glioblastoma. Cancers (Basel). 14:53772022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bouchè V, Aldegheri G, Donofrio CA,
Fioravanti A, Roberts-Thomson S, Fox SB, Schettini F and Generali
D: BRAF signaling inhibition in glioblastoma: Which clinical
perspectives? Front Oncol. 11:7720522021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Shannon S, Jia D, Entersz I, Beelen P, Yu
M, Carcione C, Carcione J, Mahtabfar A, Vaca C, Weaver M, et al:
Inhibition of glioblastoma dispersal by the MEK inhibitor
PD0325901. BMC Cancer. 17:1212017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Peng P, Wei W, Long C and Li J:
Atorvastatin augments temozolomide's efficacy in glioblastoma via
prenylation-dependent inhibition of ras signaling. Biochem Biophys
Res Commun. 489:293–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Altwairgi AK, Alghareeb WA, AlNajjar FH,
Alhussain H, Alsaeed E, Balbaid AAO, Aldanan S, Orz Y and Alsharm
AA: Atorvastatin in combination with radiotherapy and temozolomide
for glioblastoma: A prospective phase II study. Invest New Drugs.
39:226–231. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ranjbar R, Mohammadpour S, Esfahani AT,
Namazian S, Yaghob-Taleghani M, Baghaei K, Tabatabaei SA,
Pasharavesh L and Nazemalhosseini-Mojarad E: Prevalence and
prognostic role of PIK3CA E545K mutation in iranian colorectal
cancer patients. Gastroenterol Hepatol Bed Bench. 12:S22–S29.
2019.PubMed/NCBI
|
|
103
|
Liang J and Slingerland JM: Multiple roles
of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell
Cycle. 2:339–345. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zuccarini M, Giuliani P, Ziberi S,
Carluccio M, Iorio PD, Caciagli F and Ciccarelli R: The role of Wnt
signal in glioblastoma development and progression: A possible new
pharmacological target for the therapy of this tumor. Genes
(Basel). 9:1052018. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Dreyer CA, VanderVorst K, Natwick D, Bell
G, Sood P, Hernandez M, Angelastro JM, Collins SR and Carraway KL:
A complex of Wnt/planar cell polarity signaling components Vangl1
and Fzd7 drives glioblastoma multiforme malignant properties.
Cancer Lett. 567:2162802023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mueller S, Phillips J, Onar-Thomas A,
Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD,
Weiss WA, et al: PTEN promoter methylation and activation of the
PI3K/Akt/mTOR pathway in pediatric gliomas and influence on
clinical outcome. Neuro Oncol. 14:1146–1152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chang H, Cai Z and Roberts TM: The
Mechanisms underlying PTEN loss in human tumors suggest potential
therapeutic opportunities. Biomolecules. 9:7132019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Carico C, Nuño M, Mukherjee D, Elramsisy
A, Dantis J, Hu J, Rudnick J, Yu JS, Black KL, Bannykh SI and Patil
CG: Loss of PTEN is not associated with poor survival in newly
diagnosed glioblastoma patients of the temozolomide era. PLoS One.
7:e336842012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP,
To ST and Li WP: Recent advances in the use of PI3K inhibitors for
glioblastoma multiforme: Current preclinical and clinical
development. Mol Cancer. 16:1002017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wen PY, Wen PY, Yung WKA, Mellinghoff IK,
Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis
LM, et al: Rockich Xu Lager Mellinghoff Phase II trial of the
phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (bkm120)
in recurrent glioblastoma conducted by the ivy foundation early
phase clinical trials consortium. Neuro Oncol. 16 (Suppl
3):iii472014. View Article : Google Scholar
|
|
111
|
Cloughesy TF, Mischel PS, Omuro AMP,
Prados M, Wen PY and Wu B K Y JJ IK: Tumor pharmacokinetics (PK)
and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408
(XL147) administered as single agents to patients with recurrent
glioblastoma (GBM): An Ivy Foundation early-phase clinical trials
consortium study. J Clin Oncol. 31:2012. 2013. View Article : Google Scholar
|
|
112
|
Papavassiliou KA and Papavassiliou AG: The
bumpy road towards mTOR inhibition in glioblastoma: Quo vadis?
Biomedicines. 9:18092021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
England B, Huang T and Karsy M: Current
understanding of the role and targeting of tumor suppressor p53 in
glioblastoma multiforme. Tumour Biol. 34:2063–2074. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ohgaki H: Genetic pathways to
glioblastomas. Neuropathology. 25:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kim YW, Koul D, Kim SH, Lucio-Eterovic AK,
Freire PR, Yao J, Wang J, Almeida JS, Aldape K and Yung WK:
Identification of prognostic gene signatures of glioblastoma: A
study based on TCGA data analysis. Neuro Oncol. 15:829–839. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kyritsis AP, Bondy ML, Rao JS and Sioka C:
Inherited predisposition to glioma. Neuro Oncol. 12:104–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Rice T, Lachance DH, Molinaro AM,
Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis
SS, Wiemels J, Jenkins RB, et al: Understanding inherited genetic
risk of adult glioma: A review. Neurooncol Pract. 3:10–16.
2016.PubMed/NCBI
|
|
118
|
Mohyeldin A and Chiocca EA: Gene and viral
therapy for glioblastoma: A review of clinical trials and future
directions. Cancer J. 18:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Olafson LR, Gunawardena M, Nixdorf S,
McDonald KL and Rapkins RW: The role of TP53 gain-of-function
mutation in multifocal glioblastoma. J Neurooncol. 147:37–47. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sherr CJ and McCormick F: The RB and p53
pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chow LM, Endersby R, Zhu X, Rankin S, Qu
C, Zhang J, Broniscer A, Ellison DW and Baker SJ: Cooperativity
within and among Pten, p53, and Rb pathways induces high-grade
astrocytoma in adult brain. Cancer Cell. 19:305–316. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Zhang Y, Dube C, Gibert M Jr, Cruickshanks
N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K, et al:
The p53 pathway in glioblastoma. Cancers (Basel). 10:2972018.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Joerger AC and Fersht AR: Structural
biology of the tumor suppressor p53. Annu Rev Biochem. 77:557–582.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lambert JM, Gorzov P, Veprintsev DB,
Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman
KG and Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding
to the core domain. Cancer Cell. 15:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Bykov VJ, Zache N, Stridh H, Westman J,
Bergman J, Selivanova G and Wiman KG: PRIMA-1MET synergizes with
cisplatin to induce tumor cell apoptosis. Oncogene. 24:3484–3491.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zache N, Lambert JM, Wiman KG and Bykov
VJ: PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
Cell Oncol. 30:411–418. 2008.PubMed/NCBI
|
|
129
|
Patyka M, Sharifi Z, Petrecca K, Mansure
J, Jean-Claude B and Sabri S: Sensitivity to PRIMA-1MET is
associated with decreased MGMT in human glioblastoma cells and
glioblastoma stem cells irrespective of p53 status. Oncotarget.
7:60245–60269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lehmann S, Bykov VJ, Ali D, Andren O,
Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A,
et al: Targeting p53 in vivo: A first-in-human study with
p53-targeting compound APR-246 in refractory hematologic
malignancies and prostate cancer. J Clin Oncol. 30:3633–3639. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li D, Marchenko ND, Schulz R, Fischer V,
Velasco-Hernandez T, Talos F and Moll UM: Functional inactivation
of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization
of mutant p53 in human cancer cells. Mol Cancer Res. 9:577–588.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Singh MM, Johnson B, Venkatarayan A,
Flores ER, Zhang J, Su X, Barton M, Lang F and Chandra J:
Preclinical activity of combined HDAC and KDM1A inhibition in
glioblastoma. Neuro Oncol. 17:1463–1473. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liffers K, Kolbe K, Westphal M, Lamszus K
and Schulte A: Histone deacetylase inhibitors resensitize
EGFR/EGFRvIII-overexpressing, erlotinib-resistant glioblastoma
cells to tyrosine kinase inhibition. Target Oncol. 11:29–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Staberg M, Michaelsen SR, Rasmussen RD,
Villingshoj M, Poulsen HS and Hamerlik P: Inhibition of histone
deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol
(Dordr). 40:21–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Pal S, Kozono D, Yang X, Fendler W, Fitts
W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, et al: Dual HDAC and
PI3K inhibition abrogates NFκB- and FOXM1-mediated DNA damage
response to radiosensitize pediatric high-grade gliomas. Cancer
Res. 78:4007–4021. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kitange GJ, Mladek AC, Carlson BL,
Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta
SK, et al: Inhibition of histone deacetylation potentiates the
evolution of acquired temozolomide resistance linked to MGMT
upregulation in glioblastoma xenografts. Clin Cancer Res.
18:4070–4079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rasmussen RD, Gajjar MK, Jensen KE and
Hamerlik P: Enhanced efficacy of combined HDAC and PARP targeting
in glioblastoma. Mol Oncol. 10:751–763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Choi SA, Kwak PA, Park CK, Wang KC, Phi
JH, Lee JY, Lee CS, Lee JH and Kim SK: A novel histone deacetylase
inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.
Oncotarget. 8:9123–9133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Yang XF, Zhao ZJ, Liu JJ, Yang XH, Gao Y,
Zhao S, Shi S, Huang KQ and Zheng HC: SAHA and/or MG132 reverse the
aggressive phenotypes of glioma cells: An in vitro and vivo study.
Oncotarget. 8:3156–3169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Reifenberger G, Liu L, Ichimura K, Schmidt
EE and Collins VP: Amplification and overexpression of the MDM2
gene in a subset of human malignant gliomas without p53 mutations.
Cancer Res. 53:2736–2739. 1993.PubMed/NCBI
|
|
141
|
Riemenschneider MJ, Büschges R, Wolter M,
Reifenberger J, Boström J, Kraus JA, Schlegel U and Reifenberger G:
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32
in a subset of malignant gliomas without TP53 mutation or MDM2
amplification. Cancer Res. 59:6091–6096. 1999.PubMed/NCBI
|
|
142
|
Biernat W, Kleihues P, Yonekawa Y and
Ohgaki H: Amplification and overexpression of MDM2 in primary (de
novo) glioblastomas. J Neuropathol Exp Neurol. 56:180–185. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Vu B, Wovkulich P, Pizzolato G, Lovey A,
Ding Q, Jiang N, Liu JJ, Zhao C, Glenn K, Wen Y, et al: Discovery
of RG7112: A small-molecule MDM2 inhibitor in clinical development.
ACS Med Chem Lett. 4:466–469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Miles X, Vandevoorde C, Hunter A and
Bolcaen J: MDM2/X inhibitors as radiosensitizers for glioblastoma
targeted therapy. Front Oncol. 11:7034422021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Canon J, Osgood T, Olson SH, Saiki AY,
Robertson R, Yu D, Eksterowicz J, Ye Q, Jin L, Chen A, et al: The
MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and
potentiates the activity of p53-inducing cytotoxic agents. Mol
Cancer Ther. 14:649–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Her NG, Oh JW, Oh YJ, Han S, Cho HJ, Lee
Y, Ryu GH and Nam DH: Potent effect of the MDM2 inhibitor AMG232 on
suppression of glioblastoma stem cells. Cell Death Dis. 9:7922018.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Wang H, Cai S, Bailey BJ, Saadatzadeh MR,
Ding J, Tonsing-Carter E, Georgiadis TM, Gunter TZ, Long EC, Minto
RE, et al: Combination therapy in a xenograft model of
glioblastoma: Enhancement of the antitumor activity of temozolomide
by an MDM2 antagonist. J Neurosurg. 126:446–459. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Daniele S, Taliani S, Da Pozzo E,
Giacomelli C, Costa B, Trincavelli ML, Rossi L, La Pietra V,
Barresi E, Carotenuto A, et al: Apoptosis therapy in cancer: The
first single-molecule co-activating p53 and the translocator
protein in glioblastoma. Sci Rep. 4:47492014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Mosrati MA, Malmström A, Lysiak M,
Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C,
Strandéus M, Stenmark-Askmalm M and Söderkvist P: TERT promoter
mutations and polymorphisms as prognostic factors in primary
glioblastoma. Oncotarget. 6:16663–16673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Xu J, Xu FP, Liu ZH, Cui Q, Zhang KP and
Li Z: The correlation analysis of TERT promoter mutations with
IDH1/2 mutations and 1p/19q detected in human gliomas. Medicine
(Baltimore). 101:e296682022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yaltirik CK, Yilmaz SG, Ozdogan S, Bilgin
EY, Barut Z, Ture U and Isbir T: Determination of IDH1, IDH2, MGMT,
TERT and ATRX gene mutations in glial tumors. In Vivo.
36:1694–1702. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Pascolo E, Wenz C, Lingner J, Hauel N,
Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K and
Schnapp A: Mechanism of human telomerase inhibition by BIBR1532, a
synthetic, non-nucleosidic drug candidate. J Biol Chem.
277:15566–15572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Bryan C, Rice C, Hoffman H, Harkisheimer
M, Sweeney M and Skordalakes E: Structural basis of telomerase
inhibition by the highly specific BIBR1532. Structure.
23:1934–1942. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Nakashima M, Nandakumar J, Sullivan KD,
Espinosa JM and Cech TR: Inhibition of telomerase recruitment and
cancer cell death. J Biol Chem. 288:33171–33180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Aquilanti E, Kageler L, Wen PY and
Meyerson M: Telomerase as a therapeutic target in glioblastoma.
Neuro Oncol. 23:2004–2013. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Takahashi M, Miki S, Fujimoto K, Fukuoka
K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi
K, et al: Eribulin penetrates brain tumor tissue and prolongs
survival of mice harboring intracerebral glioblastoma xenografts.
Cancer Sci. 110:2247–2257. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Takahashi M, Miki S, Fukuoka K, Maida Y,
Hayashi M, Hamada A, Nishikawa R, Nagane M, Maruyama T, Mukasa A,
et al: EXTH-50. Development of investigator initiated clinical
trial of TERT-targeting therapy using eribulin mesylate in patients
with recurrent glioblastoma. Neuro Oncol. 19 (Suppl 6):vi832017.
View Article : Google Scholar
|
|
160
|
Zanetti M: A second chance for telomerase
reverse transcriptase in anticancer immunotherapy. Nat Rev Clin
Oncol. 14:115–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Reardon DA, Brandes AA, Omuro A,
Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr
O, et al: Effect of nivolumab vs bevacizumab in patients with
recurrent glioblastoma: The CheckMate 143 phase 3 randomized
clinical trial. JAMA Oncol. 6:1003–1010. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Middleton G, Silcocks P, Cox T, Valle J,
Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, et
al: Gemcitabine and capecitabine with or without telomerase peptide
vaccine GV1001 in patients with locally advanced or metastatic
pancreatic cancer (TeloVac): An open-label, randomised, phase 3
trial. Lancet Oncol. 15:829–840. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Yan J, Pankhong P, Shin TH, Obeng-Adjei N,
Morrow MP, Walters JN, Khan AS, Sardesai NY and Weiner DB: Highly
optimized DNA vaccine targeting human telomerase reverse
transcriptase stimulates potent antitumor immunity. Cancer Immunol
Res. 1:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Reardon DA, Brem S, Desai AS, Bagley SJ,
Kurz SC, De La Fuente MI, Nagpal S, Welch MR, Hormigo A, Forsyth P,
et al: LTBK-01. INO-5401 AND INO-9012 delivered intramuscularly
(IM) with electroporation (EP) in combination with cemiplimab
(REGN2810) in newly diagnosed glioblastoma. Neuro Oncol.
22:ii2372020. View Article : Google Scholar
|
|
165
|
Richters MM, Xia H, Campbell KM,
Gillanders WE, Griffith OL and Griffith M: Best practices for
bioinformatic characterization of neoantigens for clinical utility.
Genome Med. 11:562019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
You Y, Ru X, Lei W, Li T, Xiao M, Zheng H,
Chen Y and Zhang L: Developing the novel bioinformatics algorithms
to systematically investigate the connections among survival time,
key genes and proteins for Glioblastoma multiforme. BMC
Bioinformatics. 21 (Suppl 13):S3832020. View Article : Google Scholar
|
|
167
|
Shi J: Machine learning and bioinformatics
approaches for classification and clinical detection of bevacizumab
responsive glioblastoma subtypes based on miRNA expression. Sci
Rep. 12:86852022. View Article : Google Scholar : PubMed/NCBI
|
